Prescription Medication and DUI Charges
A lawful prescription is important evidence, but it is not a permission slip to drive while impaired. North Dakota separately asks whether a drug or…
North Dakota prescription medication DUI, Fargo drug-impaired driving lawyer, prescribed drugs, pharmacy warnings, opioid DUI, benzodiazepine DUI, sleep medication, drug toxicology, urine test, blood test, DRE examination, and only-as-directed affirmative defense
Prescription Medication and DUI Charges
A lawful prescription is important evidence, but it is not a permission slip to drive while impaired. North Dakota separately asks whether a drug or combination made the person incapable of driving safely and whether a prescribed drug was used only as the prescribing or dispensing practitioner directed or cautioned.
That makes a prescription-medication DUI case unusually document intensive. The bottle is only the beginning. The defense may turn on the prescription in effect that day, dose and timing, pharmacy label, medication guide, oral instructions, refill history, other medicines, alcohol, toxicology, observed driving, body camera, medical conditions, and expert testimony that distinguishes drug detection from actual impairment.
North Dakota prosecutes impairment, not the name on a pill bottle
The drug subsection requires incapacity to drive safely
Section 39-08-01(1)(a)(3) prohibits driving or actual physical control while under the influence of any drug, substance, or combination “to a degree which renders that person incapable of safely driving.” The words matter. Unlike the alcohol subsection tied to a specified chemical-test concentration, the drug subsection does not create a general numerical limit for common prescription medications.
The prosecution may use driving behavior, a crash, physical appearance, divided-attention performance, statements, possession of medication, a drug-recognition evaluation, toxicology, and expert opinion. The defense should make the State identify how each item tends to prove incapacity at the relevant time rather than allowing a medication name to substitute for the statutory element.
Alcohol and medication can support a combined-influence charge
Section 39-08-01(1)(a)(4) covers the combined influence of alcohol and other drugs or substances to the same degree of unsafe-driving incapacity. A breath or blood alcohol result below 0.08 does not end that inquiry. Prosecutors may contend that a lower alcohol concentration became impairing when combined with a sedative, opioid, sleep medicine, antihistamine, or other central-nervous-system drug.
Combination is not proved merely because two substances were detected. Timing, active compounds, metabolites, dose, tolerance, pharmacology, interactions, observed conduct, and alternative medical explanations must be evaluated. The expert should identify whether an interaction opinion is pharmacologically supported for the particular drugs and concentrations instead of invoking a vague “cocktail effect.”
A valid prescription is not an automatic defense
The opening sentence of § 39-08-01(1)(b) says that legal entitlement to use alcohol, drugs, or substances is not a defense. A defendant therefore needs more than proof that the medication was prescribed. The affirmative-defense sentence focuses on actual use: the drug must have been used only as the practitioner directed or cautioned.
That distinction prevents two common errors. The State should not argue that prescription status is irrelevant because the statute expressly creates a defense. The defense should not tell a jury that a pharmacy label alone ends the case because dose, timing, cautions, combinations, and compliance may remain disputed.
The State and defense carry different burdens
Under N.D.C.C. § 12.1-01-03(1), the State must prove each offense element beyond a reasonable doubt. Section 12.1-01-03(3) separately provides that an explicitly designated affirmative defense must be proved by the defendant by a preponderance of the evidence. The current DUI statute uses that exact designation for prescribed-drug use.
The verdict form and jury instructions should keep those burdens distinct. The defendant’s burden on the statutory defense does not relieve the prosecution of proving drug-caused unsafe-driving incapacity. Conversely, reasonable doubt about an element and proof of the affirmative defense are independent grounds that should not be collapsed into a single generalized question.
Driving and actual physical control remain essential
The medication issue does not eliminate disputes about whether anyone drove, when driving occurred, who occupied the driver’s seat, whether a parked vehicle was operable, where the keys were, or whether the location was open to public vehicular use. In a delayed-contact case, the drug level and physical observations may not reliably describe the earlier driving period.
Build the movement timeline from dispatch, surveillance, vehicle data, phone location, witnesses, receipts, body camera, and statements. A precise medication timeline cannot compensate for an unproved driving or actual-control element.
Offense-date law must be checked
The prescription-drug language has changed over time. Older versions referred to a prescribed drug that “predominately caused impairment.” The current text displayed by the Legislative Council does not contain that limitation. A lawyer should use the statute in effect on the alleged offense date and should not lift an old quotation into a current instruction.
This is especially important when reading older opinions, briefs, or pattern instructions. The reasoning may remain useful on prescribed versus nonprescribed substances, interactions, proof of compliance, or sufficiency, but an amended statute controls the present case.
State v. Bitz must be read with the statutory amendment in mind
In State v. Bitz, 2008 ND 202, ¶¶ 8–15, the North Dakota Supreme Court considered Tramadol and several detected over-the-counter substances under the statute then in effect. The Court held the jury could infer that the combination caused impairment and explained that the former protection did not extend to nonprescribed drugs or interactions involving them. It added that, on the record before it, the prescribed Tramadol alone would have fit the former exception.
Bitz is not a license to ignore toxicological limits, and its quoted statutory language is outdated. Its durable practical lesson is narrower: counsel must inventory every substance and prove the facts that bring current use within current § 39-08-01(1)(b). The present statute and evidence, not a shorthand description of the 2008 holding, should govern.
The only-as-directed-or-cautioned defense is built from records and testimony
Identify the practitioner and the prescription actually in force
Obtain the prescription order, prescriber’s name and authority, drug, formulation, strength, quantity, frequency, duration, refill authorization, and special directions. A current medication list copied forward in a chart may not establish what was ordered on the incident date. An old bottle may show historical entitlement without proving current directions.
North Dakota’s pharmacy statutes define a practitioner by legal authority to prescribe in professional practice. If the prescription came from another jurisdiction, telehealth visit, emergency department, or controlled-substance program, counsel should confirm validity without turning a routine foundation issue into needless suspicion.
“Directed” is broader than the abbreviated bottle label
A label may say “take one tablet twice daily as needed,” while the visit note supplies the condition, maximum frequency, titration schedule, taper, or special timing. Electronic after-visit instructions, patient-portal messages, discharge papers, and recorded pharmacy directions may clarify the order.
The defense should not select only the most favorable document. Compare the order transmitted to the pharmacy, medication-administration record, prescriber note, dispensing label, patient information, and testimony. Resolve discrepancies and determine which instruction the patient actually received.
“Cautioned” makes warnings central evidence
Warnings may address driving, machinery, drowsiness, dizziness, alcohol, other sedatives, meals, dose spacing, or next-day effects. Photograph the exact container and any auxiliary stickers. Obtain the medication guide and patient leaflet that accompanied the fill rather than substituting the manufacturer’s latest online label without proving it was supplied.
A warning to avoid driving until the patient knows the drug’s effects differs from an unconditional instruction never to drive. So does a caution to avoid driving for a specified number of hours after a dose. The jury should receive the actual language, date, and context rather than an officer’s paraphrase.
Oral advice can matter
Prescribers and pharmacists often give individualized counseling that never appears on the bottle. The patient may have been told to begin at night, avoid alcohol, refrain from driving during titration, wait after an as-needed dose, or resume driving after stable use without adverse effects. Document that advice lawfully and early.
A provider’s later statement should distinguish charted recollection from customary practice. Testimony that “I always warn patients” is different from a note recording the exact warning given here. Both may be admissible, but the evidentiary weight and foundation are not identical.
Dose, interval, and formulation must match
Immediate-release and extended-release products can have different timing and risks. Splitting a tablet, doubling after a missed dose, taking an extra as-needed dose, using the medicine sooner than permitted, or combining duplicate products may place use outside the defense even though the bottle bears the defendant’s name.
Build a dose chart from refill records, remaining count when reliable, electronic dispensers, caregiver logs, messages, medical records, and candid testimony. Toxicology may support or contradict the history, but concentration alone often cannot reconstruct exact dosing.
Alcohol, other prescriptions, and over-the-counter products require a complete audit
A prescriber may direct a drug correctly while cautioning against alcohol or other sedatives. Another provider may prescribe an interacting medicine without knowing the first. Nighttime cold products, antihistamines, sleep aids, motion-sickness drugs, supplements, cannabis products, and borrowed pills can change both the pharmacology and the statutory analysis.
Ask about products by symptom and brand, not merely “medications.” People may not regard diphenhydramine, melatonin, cough syrup, CBD, or a leftover pain pill as a drug worth mentioning. The defense is stronger when it finds and evaluates an unfavorable substance before the laboratory or prosecutor does.
Proof should establish compliance, not merely access
Useful exhibits include the original container, certified pharmacy profile, dispensing log, prescriber order, instructions, contemporaneous chart, medication guide, refill dates, pill count, caregiver records, and testimony about the dose actually taken. A prescription database entry may prove dispensing but not consumption or compliance.
Do not assume the prosecution can obtain every record without process or that the defense should waive all medical privacy. Identify the narrow records necessary for the defense, review them for other sensitive material, use appropriate releases or court procedures, and anticipate evidentiary authentication.
Deviations require precise legal and factual analysis
A minor timing variation is not automatically equivalent to misuse, but the statutory word “only” makes material compliance important. The case should address what the direction allowed, what occurred, whether any deviation affected concentration or driving ability, and whether the prosecution can still prove incapacity.
Even if the affirmative defense is unavailable because of a deviation, the State still carries its burden on the offense elements. The absence of a defense is not proof that the person was incapable of driving safely.
Different medication classes create different proof problems
Opioid cases require more than the word “narcotic”
Opioids can cause sedation, slowed reaction, dizziness, nausea, and respiratory effects, particularly after a new prescription, dose increase, or combination with other depressants. Long-term patients may develop tolerance to some effects. Neither pharmacological possibility answers whether this driver was incapable of driving safely at this time.
Identify the parent drug, metabolites, formulation, dose, time, treatment duration, tolerance evidence, co-medications, alcohol, and observed conduct. A metabolite may confirm exposure without proving when the active drug was taken or what functional effect remained.
Benzodiazepines and other anti-anxiety medicines can complicate coordination evidence
Benzodiazepines may affect alertness, memory, balance, and divided attention. Their duration varies substantially by drug, metabolite, dose, chronic use, age, and coadministration. A prosecution expert should not transfer an effect profile from one benzodiazepine to another without explanation.
Anxiety itself can affect roadside performance and communication. The defense should separate the condition, treatment, acute stress, and toxicology. Medical records can support an explanation, but counsel should avoid broad claims that anxiety accounts for every objective sign.
Sleep medicines raise residual next-morning questions
Some insomnia drugs can affect driving the next morning even when the patient feels awake. The FDA’s current driving guidance advises patients to discuss the lowest effective dose, dose timing, and when driving can safely resume. The FDA’s zolpidem information specifically addresses next-morning impairment concerns.
For a morning stop, reconstruct bedtime, dose, awakening, sleep duration, nighttime redosing, food, formulation, and concurrent depressants. “Taken last night” is not a sufficient pharmacokinetic history.
Muscle relaxants, gabapentinoids, and antiseizure drugs need drug-specific analysis
These categories include medicines with different mechanisms and adverse-effect profiles. Drowsiness, dizziness, blurred vision, or coordination problems may occur, but the underlying pain, spasm, neuropathy, or seizure disorder may also affect roadside observations.
Determine whether treatment was newly started, stable, increased, tapered, or taken as needed. Review renal function where medically relevant, other sedatives, and the exact warning. A broad class label is not a substitute for an opinion about the identified drug.
Antidepressants and antipsychotics should not be treated as proof of incapacity
Some medicines in these groups may cause sedation, activation, dizziness, visual effects, or orthostatic symptoms. Many patients take them without unsafe driving effects. Diagnosis and prescription are not character evidence and should not be used to invite stigma.
Limit disclosure to relevant medical facts and seek appropriate protections. The prosecution expert should connect the drug, timing, concentration when meaningful, and observations to the statutory impairment question rather than reciting a package insert’s complete list of possible adverse events.
Stimulants can produce a different pattern
Prescription stimulants may be used for attention disorders or sleep disorders. A therapeutic dose may improve the treated patient’s attention, while excessive use can produce agitation, rapid speech, tremor, cardiovascular effects, insomnia, or poor judgment. Detection alone does not show which situation existed.
Review formulation, daily schedule, refill timing, sleep history, dose changes, other stimulants, and observed behavior. Amphetamine findings also require careful identification of isomers and possible sources when the analytical method or issue makes that distinction relevant.
Antihistamines and cold products are easy to overlook
The FDA warns that some antihistamines can slow reaction, impair focus, and cause confusion even without perceived drowsiness. Combination cold and nighttime products may contain sedating ingredients plus acetaminophen, cough suppressants, or decongestants. Duplicate-brand use can unintentionally increase exposure.
Prescribed status may be absent for an over-the-counter product. Under current § 39-08-01(1)(b), counsel should analyze whether a practitioner actually prescribed or dispensed the particular drug and what directions or cautions applied, rather than assuming every lawful purchase fits the affirmative defense.
The federal safety message is useful but not a verdict
NHTSA advises a person with a new prescription or increased dose not to drive until the effects on judgment, coordination, and reaction time are known. The agency also notes that a medication may become impairing with another medication or alcohol. That public-safety advice supports careful individualized assessment.
It does not establish that every user of a listed medicine was legally impaired. A court must decide the charged case from admissible evidence. General guidance can frame the inquiry, but incident-specific proof remains essential.
The best defense compares the entire encounter with the alleged drug effect
Driving evidence should be described accurately
Separate a citizen report from an officer’s own observation. Identify duration, distance, traffic, road design, weather, lane markers, speed, braking, signals, and whether the conduct has an ordinary explanation. A single lane touch is different from repeated near collisions; a crash is not self-proving drug impairment.
Obtain squad video, traffic cameras, business video, vehicle telematics, crash reconstruction, and dispatch audio. An officer’s report may compress a long period into adjectives that the recording does not fully support.
Body camera can reveal normal abilities omitted from the report
Review how the person parked, found documents, used a phone, understood questions, recalled events, followed instructions, walked, stood, and interacted over time. Note slurred speech, eyelid appearance, nodding, confusion, repetition, or delayed responses, but compare the characterization with the actual audio and video.
A person can be impaired without dramatic signs, and competent behavior does not conclusively prove safety. Still, an expert opinion should account for contrary performance rather than relying only on selected clues.
Field sobriety tests were developed principally for alcohol investigation
Horizontal gaze nystagmus, walk-and-turn, and one-leg stand observations may contribute to an investigation, but drug effects vary and not every medication produces the same signs. The test conditions, instructions, demonstration, footwear, surface, lighting, weather, injury, age, and medical limitations must be documented.
Do not reduce the recording to “passed” or “failed.” Count the officer’s claimed clues, verify them against video, and determine whether the officer administered and interpreted the exercise according to the training being invoked. Nonstandard tasks should be labeled and evaluated for what they actually demonstrate.
A drug-recognition evaluation is an opinion process, not a laboratory result
A DRE examination may include breath testing, an interview, eye examinations, divided-attention tasks, vital signs, dark-room pupil measurements, muscle tone, injection-site review, statements, and a toxicological sample. Obtain every worksheet, times, measurements, training record, notes, and recording.
Compare the evaluator’s predicted category with the confirmed findings and known prescription. Examine whether medical conditions, anxiety, lighting, measurement technique, or timing explain claimed signs. A category opinion still must help prove the statutory level of unsafe-driving incapacity.
Medical conditions can mimic or magnify alleged drug signs
Fatigue, sleep disorders, diabetes, neurological disease, eye conditions, vestibular disorders, pain, migraine, dehydration, infection, low blood pressure, anxiety, concussion, and orthopedic limitations can affect appearance or performance. Emergency symptoms may also explain unusual driving.
The defense should not diagnose from video. Obtain contemporaneous records and qualified medical interpretation. Determine whether the condition explains the sign, whether the medication treated it, and whether either affected safe driving.
Statements about medication require context and precision
Roadside questions often produce incomplete answers: “What are you taking?” “When did you last take it?” “Does it make you tired?” Preserve the exact words, sequence, warnings, custody circumstances, and recording. A person may not know a generic name, dose, or metabolite under stress.
A statement that a medicine “can make me sleepy” is not an admission of sleepiness while driving. Conversely, an admission of extra doses, alcohol mixing, recent titration, or feeling impaired can be significant. Litigate voluntariness and suppression where appropriate, but prepare to address admissible statements factually.
The timeline should include treatment, sleep, food, and driving
Create a minute-by-minute chart for the last normal dose, any as-needed dose, meals, alcohol, other drugs, sleep, awakening, departure, driving, stop, arrest, DRE, sample collection, and later medical care. Use ranges where exact time is unknown.
Connect each time to a source: bottle, phone reminder, caregiver, portal message, receipt, camera, dispatch, instrument, phlebotomy record, or laboratory accession. A transparent range is more credible than false precision.
Preservation should begin immediately
Send lawful preservation demands for body and squad camera, dispatch, jail and station video, DRE room video, hospital samples, laboratory specimens, business cameras, and pharmacy records. Request the original digital files and metadata when important, not only a compressed portal copy.
Keep the original container and do not alter its contents merely to create evidence. Photograph the label and pills, document custody, and consult counsel before independent testing. Evidence preservation must be ethical and reproducible.
A positive drug test answers only part of the case
Blood and urine provide different information
Blood can show parent drugs and metabolites circulating at collection time and may sometimes permit concentration-based interpretation. Urine generally shows what the body excreted over a bladder interval and can remain positive after functional effects have diminished. The matrices are not interchangeable.
Ask what specimen was collected, when, whether the laboratory screened or confirmed, what compounds were reported, whether results were qualitative or quantitative, and what the method can support. A urine-positive result should not be presented as a measured blood concentration.
Detection is not the same as impairment
A laboratory can reliably identify a drug and still be unable to determine whether the person was incapable of safely driving. The inference depends on matrix, concentration, sampling delay, dose, active compound, metabolite, pharmacokinetics, tolerance, interactions, and behavior.
The expert should state the limits directly. “Consistent with use” may be sound; “therefore impaired” may not be. A prosecutor may prove impairment circumstantially, but the laboratory report should not be assigned a conclusion it cannot carry.
Therapeutic ranges are not a bright line
A published therapeutic range may refer to a population, clinical monitoring purpose, specimen timing, laboratory method, or disease indication. A result within the range does not guarantee safe driving, and a result above it does not automatically prove statutory incapacity.
Require the witness to identify the source, specimen, sampling time, population, and relevance of any range. Compare the laboratory’s units and free-versus-total measurement. Avoid the misleading suggestion that a single table functions like the alcohol per-se limit.
Parent drugs and metabolites must be identified correctly
An active metabolite may contribute to effect; an inactive metabolite may primarily document prior exposure. Some compounds arise from more than one source. The report should use exact names and explain what each finding can and cannot establish.
Screening immunoassays can cross-react and usually require appropriate confirmation for a contested identification. Obtain validation, cutoff, chromatograms, spectra or ion criteria, calibrators, controls, analyst notes, and uncertainty information relevant to the reported method.
Collection and chain of custody remain contestable
For blood, examine legal authority, collector qualification, kit, tubes, expiration, antiseptic, mixing, seals, labeling, storage, transport, and accession. For urine, examine privacy, identity, container, seal, temperature or other integrity measures when used, storage, and the time since prior void.
A clerical discrepancy does not automatically invalidate a result. The question is whether identity, integrity, method, or interpretation is genuinely affected. Build a defect-specific argument supported by records and expert testimony.
North Dakota’s chemical-testing chapter controls officer-directed tests
N.D. Cent. Code ch. 39-20 addresses officer-directed blood, breath, oral-fluid, and urine testing for alcohol concentration or the presence of drugs, with the officer selecting the test after arrest under § 39-20-01. Search warrants, consent, serious-injury or fatal-crash provisions, and constitutional limits may also matter.
Separate lawful acquisition from analytical foundation. A valid warrant does not prove the sample was properly identified or tested, and a scientifically reliable result does not cure an unconstitutional search.
Certified reports and analyst testimony require deadline control
Section 39-20-07 supplies statutory foundation rules for approved methods, qualified collectors, certified records, and chemical analyses. N.D.R.Ev. 707 governs notice of intent to use an analytical report and a defendant’s demand for the analyst, including specified advance deadlines.
Calendar every notice and demand date immediately. Requesting the wrong witness can waste the opportunity: collection, accession, screening, confirmation, technical review, and interpretation may involve different people. Identify which contested proposition requires which witness.
Independent testing may preserve critical information
Section 39-20-02 addresses an opportunity for an additional chemical test at the person’s expense after an officer-directed test. Whether a usable sample remains later depends on specimen, amount, laboratory policy, preservation, and court orders.
Move promptly for preservation and access when retesting could matter. Consult an independent laboratory and expert before consuming limited material. Retesting should use a method capable of addressing the actual identification or concentration dispute.
Expert testimony should connect pharmacology to the actual facts
The toxicologist must fit the opinion offered
N.D.R.Ev. 702 requires relevant specialized knowledge from a qualified witness and reliable application to sufficient facts. A laboratory analyst may be qualified to explain the method without being qualified to diagnose a medical condition or give a sweeping functional-impairment opinion.
Examine education, forensic experience, drug-specific knowledge, clinical versus postmortem data, driving research, validation familiarity, and testimony history. Qualification is opinion specific, not a lifetime credential to say anything about drugs.
The opinion must disclose its factual bases
N.D.R.Ev. 703 addresses the facts or data on which an expert relies. Require disclosure of reports, raw data, medical records, dose history, timelines, literature, databases, assumptions, calculations, and contrary information.
An opinion that assumes the officer’s conclusion, guesses the dose, ignores the collection delay, and treats every listed side effect as present is vulnerable. A sound opinion separates measured facts, reported history, assumed facts, and scientific generalizations.
Package inserts describe risks, not incident-specific performance
Labeling can establish approved warnings and known adverse reactions, but a possible effect is not proof that the effect occurred. Frequency, dose, population, combination, and timing matter. Ask whether the expert has evidence that this defendant experienced the cited effect.
At the same time, the defense should not dismiss a clear driving warning. The warning may be central to the statutory “cautioned” question. Use the correct version and prove what was communicated.
Driving studies require careful translation
On-road, simulator, psychomotor, and epidemiological studies answer different questions. Healthy volunteers receiving a single dose may differ from a stable patient. A study’s drug, dose, formulation, time after dose, comparison group, outcome, and limitations should be placed on the record.
The FDA’s guidance on evaluating drug effects on driving discusses central-nervous-system effects and residual impairment in drug development. It is a useful framework, not proof of guilt in an individual prosecution.
Prescribers and pharmacists can supply different testimony
The prescriber may explain the diagnosis, order, titration, instructions, cautions, treatment duration, response, and relevant medical conditions. The pharmacist may authenticate dispensing, labels, auxiliary warnings, counseling, interactions, refill history, and customary procedures.
Neither witness should be pushed beyond expertise. A treating clinician may not be a forensic toxicologist, and a toxicologist may not know what advice the patient actually received. Coordinate the proof so each witness addresses a defined issue.
Tolerance must be presented with restraint
Chronic exposure can reduce some observable effects, but tolerance is drug and effect specific. It does not mean the person is immune to impairment, and it cannot be assumed solely from refill history. Abrupt dose changes, missed doses, illness, sleep deprivation, and co-use may alter response.
A defense expert should explain the supporting clinical and behavioral facts and acknowledge limits. Overclaiming tolerance can alienate a jury and invite evidence of dependence or misuse that otherwise had little relevance.
Cross-examination should move from result to inference
Confirm the specimen, collection time, method, reported compound, concentration if any, uncertainty, and what the result directly proves. Then address dose inference, time of use, active effect, therapeutic range, individual variability, interactions, observations, and the statutory incapacity standard.
Short, proposition-specific questions are more effective than asserting that toxicology is meaningless. The defense can accept a correct identification while demonstrating that the conclusion about driving ability exceeds the data.
A disciplined defense coordinates suppression, science, and the affirmative defense
Start with the exact charging theory
Obtain the complaint, information, probable-cause statement, and bill of particulars where appropriate. Determine whether the State alleges a drug, combination of drugs, combined alcohol and drugs, refusal, or alternative theories. Identify every charged subsection and the alleged time and location.
A prescription defense may answer one drug while another substance supports the prosecution’s theory. Motions, experts, and negotiations should track the actual charge rather than a generic “medication DUI” label.
Litigate the stop, arrest, search, and statements separately
Review reasonable suspicion for the stop, community-caretaking claims, expansion of the encounter, field testing, probable cause, custody, interrogation, consent, warrant scope, and execution. A medicine bottle seen in the car does not by itself establish impairment.
Suppressing an unlawful blood or urine test may materially change the case, but observed driving and statements may remain. A lawful sample can still be challenged on foundation and interpretation. Keep constitutional, evidentiary, and merits arguments distinct.
Build both the element defense and affirmative defense
The element defense asks whether the State can prove a drug or combination made the person incapable of safely driving. It may rely on normal driving, competent behavior, medical alternatives, delayed testing, and toxicological limits. The affirmative defense asks whether the prescribed drug was used only as directed or cautioned.
Presenting both is not inconsistent when the evidence supports them: “The State did not prove incapacity, and the prescribed drug was in any event used exactly as directed and cautioned.” Instructions and closing should preserve the separate burdens.
Prepare for unfavorable records before disclosing the defense
Medical and pharmacy records may reveal warnings, early refills, missed appointments, multiple prescribers, prior adverse effects, substance-use concerns, or an instruction not to drive. Review the complete relevant set before making factual representations or broad waivers.
An unfavorable fact may require a narrower theory, a different expert assignment, a motion in limine, or candid negotiation. Concealing it from the defense expert creates a fragile opinion and an avoidable credibility problem.
Use discovery requests that demand the underlying science
Request the complete forensic file: submissions, chain, screening, confirmation, quantitative data, chromatograms, spectra, calibrators, controls, batch records, quality review, validation, uncertainty, proficiency, maintenance, corrective actions, and communications. Seek DRE materials, training, video, reports, medical-response records, and every version of the officer narrative.
Tailor requests to the laboratory and issue. A massive generic demand can obscure the missing item. Follow the laboratory’s identifiers and compare the file against its method and reporting policy.
Administrative license consequences need a separate calendar
North Dakota’s administrative case can involve refusal or an alcohol test at a statutory concentration. A positive prescription-drug finding does not automatically create the same per-se administrative suspension theory as an over-limit alcohol result. The Report and Notice and current chapter 39-20 must be read carefully.
Do not assume the criminal court schedule protects driving privileges. Preserve the short NDDOT hearing deadline when a temporary permit or revocation notice was issued, and coordinate testimony without unnecessarily revealing privileged defense work.
Negotiation should use a verified, concise record
A useful presentation may include the valid prescription, exact instruction, label and caution, fill history, dose timeline, toxicology limitations, video excerpts, medical explanation, and a focused expert letter. Explain how the materials affect a statutory element or the affirmative defense.
Avoid promising that “prescribed means legal.” Accurate advocacy is more persuasive. If a non-driving resolution, reduction, or dismissal is sought, address public safety, treatment stability, transportation planning, and preservation of necessary medication without stigmatizing lawful care.
Trial should teach the difference between presence and incapacity
Use a simple timeline and a table that separates detected compound, specimen, collection time, direct meaning, unknowns, prescribed direction, and observed behavior. Redact irrelevant private information. Demonstratives should clarify evidence rather than function as unsworn expert opinions.
In closing, return to the statutory words. Identify what the State proved, what its expert assumed, why the observations do or do not show unsafe-driving incapacity, and how the defense evidence satisfies “only as directed or cautioned” if that issue is submitted.
Frequently asked questions about prescription medication DUI charges
1. Can I get a DUI in North Dakota for prescription medication?
Yes. Section 39-08-01 applies when a drug, substance, or combination renders a person incapable of safely driving, even if the drug was lawfully obtained. A separate affirmative defense may apply to a drug used only as the prescribing or dispensing practitioner directed or cautioned.
2. Is showing the prescription bottle enough?
No. The bottle helps prove dispensing, but the defense may also require the current order, dose, timing, cautions, actual use, other substances, and witness or pharmacy evidence.
3. Who has the burden on the prescription-drug defense?
North Dakota generally requires the defendant to prove an expressly designated affirmative defense by a preponderance of the evidence. The State still must prove every offense element beyond a reasonable doubt.
4. What does “only as directed or cautioned” mean?
It focuses on compliance with the practitioner’s dosing directions and relevant cautions, which may appear in the prescription, label, medication guide, visit instructions, portal messages, or oral counseling.
5. Does a warning not to operate heavy machinery include driving?
It generally can. The exact warning, timing, and context matter. NHTSA specifically advises that heavy-machinery warnings include motor vehicles.
6. What if I did not feel impaired?
Self-perception is relevant but not controlling. Some medicines can affect reaction, focus, or coordination without obvious sleepiness. The case should compare toxicology, timing, warnings, driving, and recorded behavior.
7. Can a therapeutic drug level prove I was safe to drive?
No. A therapeutic range is not a universal driving-safety limit. It may be useful context, but its specimen, timing, population, and clinical purpose must be explained.
8. Does a positive urine test prove impairment?
No. Urine commonly documents prior exposure over a bladder interval and may remain positive after effects diminish. The State may use other evidence, but a urine finding alone does not measure driving ability.
9. Is a blood test stronger than a urine test?
Blood can provide more time-specific information and sometimes a concentration, but interpretation remains drug specific. Collection delay, active metabolites, tolerance, interactions, method, and observed behavior still matter.
10. What if I mixed medication with alcohol?
The State may charge combined influence, even when the alcohol concentration is below 0.08. The combination may also conflict with a practitioner’s caution and affect the affirmative defense.
11. Can over-the-counter medicine cause a DUI?
Yes. Sedating antihistamines, sleep aids, cough products, and other lawful substances can contribute to unsafe-driving incapacity. Current prescription-defense language must be analyzed carefully because a retail purchase is not necessarily a drug prescribed or dispensed to the person by a practitioner.
12. What is a drug-recognition evaluation?
It is a structured police evaluation using interviews, eye checks, divided-attention tasks, vital signs, pupil measurements, physical observations, and toxicology. The methods, measurements, video, medical alternatives, and match between the predicted category and laboratory result can be challenged.
13. Can tolerance be a defense?
Tolerance may affect how a chronic patient responds, but it is not complete immunity from impairment. It needs drug-specific, clinical, behavioral, and expert support.
14. Should my doctor or pharmacist testify?
Possibly. A prescriber can explain the order, directions, cautions, treatment, and medical condition. A pharmacist can address dispensing, labels, warnings, interactions, counseling, and refill history. Each witness should stay within the witness’s expertise.
15. Can the State use my private medical records?
Relevant records may be obtained through lawful process or a defense release, but medical privacy and evidentiary limits still matter. Counsel should identify the necessary records, review them before disclosure, and seek protection for irrelevant material.
16. What evidence should be saved immediately?
Save the original bottle and paperwork, prescription and visit instructions, pharmacy profile, medication guide, receipts, messages, dose reminders, body and squad video, DRE materials, laboratory samples and raw data, witnesses, and any video showing driving or condition.
17. Does State v. Bitz still control current cases?
It remains a North Dakota decision, but it interpreted older statutory language containing a predominance limitation that the current text omits. Its reasoning must be applied only after checking the offense-date statute and present evidence.
18. What is the first step in defending a prescription-medication DUI?
Identify the exact charge and deadlines, preserve video and specimens, collect the complete prescription and caution record, create a dose-and-driving timeline, inventory every substance, and have qualified counsel and experts review the raw toxicology before making broad claims.